相关实验视频

Updated: Jul 3, 2025

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

亲属阿尔茨海默氏症突变稳定了合成毒的γ-分泌酶-基质复合体

Sujan Devkota¹, Rui Zhou², Vaishnavi Nagarajan¹

¹Department of Medicinal Chemistry, University of Kansas, Lawrence, KS, USA.

|February 13, 2024

概括

家族性阿尔茨海默病 (FAD) 突变破坏了由γ-分泌酶处理的粉样蛋白前体蛋白 (APP). 这种停滞不前的过程,而不是粉样β (Aβ) 的产生,驱动着FAD的病原性.

科学领域:

神经科学是一个神经科学.
分子生物学分子生物学
生物化学生物化学

背景情况:

家庭性阿尔茨海默病 (FAD) 与粉样蛋白前体蛋白 (APP) 和 presenilin 中的突变有关,影响粉样β (Aβ) 的产生.
作为FAD的主要驱动因素的Aβ的确切作用仍在争论中,这促使人们对替代性致病机制进行研究.

研究的目的:

调查FAD突变如何影响APP基质C99.9的γ-分泌酶介导加工中的初始蛋白质分解步骤.
确定Aβ的积累或酶过程本身的破坏是否对FAD病原体产生负责.

主要方法:

使用冷电子显微镜捕捉了与APP C99基质模拟器结合的γ-分泌酶的过渡状态.
采用分子动力学模拟和in silico建模来分析酶基质相互作用.
通过细胞光显微镜和神经元表达研究在Caenorhabditis elegans中进行,以评估突触损失.

主要成果:

发现FAD突变破坏了由γ-分泌酶在C99处理中的初始蛋白质分解事件.
低温电子显微镜揭示了一个稳定的酶基质复合结构,进一步得到了分子动力学模拟的支持.
在C. elegans中,FAD突变C99或 presenilin-1的神经表达诱导了突触损失,也观察到突变稳定了酶基质复合体并阻止了Aβ产生.

结论:

这些发现表明,停滞不前的γ-分泌酶裂变过程,而不是由此产生的Aβ产物,是FAD发病的关键因素.
由FAD突变型γ-分泌酶破坏APP基质的酶处理是阿尔茨海默病中突触功能障碍的关键机制.

关键词:

这里是C. elegans.科普:分子生物学分子生物学科普:神经科学是什么意思低温电子显微镜的使用方法光显微镜的光显微镜.分子动力学分子动力学神经退行症的神经退行症蛋白质结构蛋白质结构蛋白质溶解过程中的蛋白质溶解.

更多相关视频

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

相关概念视频

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...